Structure |
Chemical Name |
CAS |
MF |
![KXEITTOLAUJQPU-UHFFFAOYSA-N](/CAS/20210111/GIF/1797832-43-9.gif) |
KXEITTOLAUJQPU-UHFFFAOYSA-N |
1797832-43-9 |
C20H21N7O2S |
![GPZGXSFHPLUMHE-KEUNHQLVSA-N](/CAS/20211123/GIF/157054-84-7.gif) |
GPZGXSFHPLUMHE-KEUNHQLVSA-N |
157054-84-7 |
C52H81NO13 |
![IRLGOHSHDYCIAB-ZMVBZRCWSA-N](/CAS/20200611/GIF/1076198-14-5.gif) |
IRLGOHSHDYCIAB-ZMVBZRCWSA-N |
1076198-14-5 |
C19H23F3N2O5 |
![AOEGVETYSHPGBP-XYIDDFOTSA-N](/CAS/20210111/GIF/1887057-05-7.gif) |
AOEGVETYSHPGBP-XYIDDFOTSA-N |
1887057-05-7 |
C41H55NO14 |
![12-Deoxy Roxithromycin](/CAS/20211123/GIF/425365-65-7.gif) |
12-Deoxy Roxithromycin |
425365-65-7 |
C41H76N2O14 |
![1-(1-oxidopyridin-1-ium-2-yl)-1-phenylethanol](/CAS/20200119/GIF/100393-43-9.gif) |
1-(1-oxidopyridin-1-ium-2-yl)-1-phenylethanol |
100393-43-9 |
C13H13NO2 |
![(R)-(R)-1-methylpyrrolidin-3-yl 2-cyclopentyl-2-hydroxy-2-phenylacetate(WXC03446)](/CAS/20180808/GIF/616866-21-8.gif) |
(R)-(R)-1-methylpyrrolidin-3-yl 2-cyclopentyl-2-hydroxy-2-phenylacetate(WXC03446) |
616866-21-8 |
C18H25NO3 |
![6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-5-amine](/CAS/20180703/GIF/CB43956117.gif) |
6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-5-amine |
|
C18H17N3O2S |
![Diquafosol Impurity 4](/) |
Diquafosol Impurity 4 |
|
|
![Tofacitinib Impurity X](/) |
Tofacitinib Impurity X |
|
|
![3-pentylideneisobenzofuran-1(3H)-one](/CAS/20180703/GIF/90965-68-7.gif) |
3-pentylideneisobenzofuran-1(3H)-one |
90965-68-7 |
C13H14O2 |
![(R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl propionate](/CAS/20200401/GIF/CB83129539.gif) |
(R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl propionate |
|
C25H35NO3 |
![Flomoxef Impurity 4](/) |
Flomoxef Impurity 4 |
|
|
![Nicardipine Impurity 5](/) |
Nicardipine Impurity 5 |
|
|
![11,11'-(PIPERAZINE-1,4-DIYL)-BIS-8-CHLORO-5H-DIBENZE[B,E][1,4]-DIAZEPINE](/CAS/GIF/263366-81-0.gif) |
11,11'-(PIPERAZINE-1,4-DIYL)-BIS-8-CHLORO-5H-DIBENZE[B,E][1,4]-DIAZEPINE |
263366-81-0 |
C30H24Cl2N6 |
![Sacubitril Impurity 7](/CAS/20180713/GIF/149709-44-4.gif) |
Sacubitril Impurity 7 |
149709-44-4 |
C22H25NO5 |
![Valsartan Impurity 5](/CAS/20180703/GIF/1266616-11-8.gif) |
Valsartan Impurity 5 |
1266616-11-8 |
C18H21N5 |
![Milnacipran Impurity 4](/CAS/20210111/GIF/1353644-49-1.gif) |
Milnacipran Impurity 4 |
1353644-49-1 |
C15H21NO2 |
![5-[[4-(Hydroxymethyl)phenoxy]methyl]-3-(1-methylethyl)-2-oxazolidinone](/CAS/20150408/GIF/1071765-44-0.gif) |
5-[[4-(Hydroxymethyl)phenoxy]methyl]-3-(1-methylethyl)-2-oxazolidinone |
1071765-44-0 |
C14H19NO4 |
![(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol 2,3,4,6-tetrakis(2,2-dimethylpropanoate)](/CAS/20180906/GIF/1283129-18-9.gif) |
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol 2,3,4,6-tetrakis(2,2-dimethylpropanoate) |
1283129-18-9 |
C44H57FO9S |
![1,4′-ビピペリジン-1′-カルボン酸](/CAS/20150408/GIF/1026078-50-1.gif) |
1,4′-ビピペリジン-1′-カルボン酸 |
1026078-50-1 |
C11H20N2O2 |
![4-[[3-(1-Methylethyl)-2-oxo-5-oxazolidinyl]methoxy]benzaldehyde](/CAS/20150408/GIF/1173203-26-3.gif) |
4-[[3-(1-Methylethyl)-2-oxo-5-oxazolidinyl]methoxy]benzaldehyde |
1173203-26-3 |
C14H17NO4 |
![EMpagliflozin iMpurity 9](/) |
EMpagliflozin iMpurity 9 |
|
|
![EMpagliflozin iMpurity 14](/CAS/20211123/GIF/2137418-13-2.gif) |
EMpagliflozin iMpurity 14 |
2137418-13-2 |
C23H27ClO8 |
![ibrutinib iMpurity A](/) |
ibrutinib iMpurity A |
|
|
![Sunitinib iMpurity E](/) |
Sunitinib iMpurity E |
|
|
![Rosuvastatin EP impurity H](/CAS/20210111/GIF/1335110-44-5.gif) |
Rosuvastatin EP impurity H |
1335110-44-5 |
C22H28FN3O6S |
![Saxagliptin Impurity 4 (Deoxy Saxagliptin)](/) |
Saxagliptin Impurity 4 (Deoxy Saxagliptin) |
|
|
![Betamethasone EP Impurity D](/CAS/20180629/GIF/52619-05-3.gif) |
Betamethasone EP Impurity D |
52619-05-3 |
C25H33FO7 |
![Dihydropenicillin F Potassium Salt](/CAS/20211123/GIF/31447-86-6.gif) |
Dihydropenicillin F Potassium Salt |
31447-86-6 |
C14H23KN2O4S |
![Etoricoxib Impurity 7](/CAS/20200611/GIF/646459-39-4.gif) |
Etoricoxib Impurity 7 |
646459-39-4 |
C20H21N3O2S |
![Mupirocin Impurity D](/CAS/20180629/GIF/CB12741867.gif) |
Mupirocin Impurity D |
|
C26H44O9 |
![Phenylephrine EP Impurity D](/CAS/20180629/GIF/1367567-95-0.gif) |
Phenylephrine EP Impurity D |
1367567-95-0 |
C16H19NO2 |
![Verapamil Impurity O](/CAS/20180629/GIF/959011-16-6.gif) |
Verapamil Impurity O |
959011-16-6 |
C27H38N2O4 |
![1,1′-(イソプロピルイミノ)ビス[3-[4-(2-メトキシエチル)フェノキシ]-2-プロパノール]](/CAS/20211123/GIF/1486464-40-7.gif) |
1,1′-(イソプロピルイミノ)ビス[3-[4-(2-メトキシエチル)フェノキシ]-2-プロパノール] |
1486464-40-7 |
C27H42ClNO6 |
![4'-FLUOROCYCLOPROPANECARBOXANILIDE](/CAS/20180629/GIF/2354-89-4.gif) |
4'-FLUOROCYCLOPROPANECARBOXANILIDE |
2354-89-4 |
C10H10FNO |
![(Z)-2-(2-Aminothiazol-4-yl)-2-(1-carboxy-1-methyl)ethoxyiminoacetic acid](/CAS/GIF/102507-85-7.gif) |
(Z)-2-(2-Aminothiazol-4-yl)-2-(1-carboxy-1-methyl)ethoxyiminoacetic acid |
102507-85-7 |
C9H11N3O5S |
![Cefaclor EP IMpurity](/) |
Cefaclor EP IMpurity |
|
|
![Linagliptin Impurity F](/CAS/20180808/GIF/1673546-62-7.gif) |
Linagliptin Impurity F |
1673546-62-7 |
C27H27F3N8O3 |
![Parecoxib Impurity D](/) |
Parecoxib Impurity D |
|
|
![Parecoxib Impurity I](/) |
Parecoxib Impurity I |
|
|
![Lenvatinib Impurity d](/CAS/20180808/GIF/417717-04-5.gif) |
Lenvatinib Impurity d |
417717-04-5 |
C20H17ClN4O4 |
![4-ブロモ-3-(ヒドロキシメチル)フェノール](/CAS/GIF/2737-20-4.gif) |
4-ブロモ-3-(ヒドロキシメチル)フェノール |
2737-20-4 |
C7H7BrO2 |
![4-(4-Bromo-3-formyl-phenoxy)-benzonitrile](/CAS/GIF/906673-54-9.gif) |
4-(4-Bromo-3-formyl-phenoxy)-benzonitrile |
906673-54-9 |
C14H8BrNO2 |
![Linagliptin Impurity I](/) |
Linagliptin Impurity I |
|
|
![1H-Pyrrole-3-carbonitrile,5-(2-fluorophenyl)-1-(3-pyridinylsulfonyl)-](/CAS/20180629/GIF/1807642-39-2.gif) |
1H-Pyrrole-3-carbonitrile,5-(2-fluorophenyl)-1-(3-pyridinylsulfonyl)- |
1807642-39-2 |
C16H10FN3O2S |
![4-amino-1-[(2RS)-2-(2,4-difluorophenyl)-2-hydroxy-3(1H-
1,2,4-triazol-1-yl)propyl]-4H-1,2,4-triazolium](/CAS/20180629/GIF/749821-19-0.gif) |
4-amino-1-[(2RS)-2-(2,4-difluorophenyl)-2-hydroxy-3(1H-
1,2,4-triazol-1-yl)propyl]-4H-1,2,4-triazolium |
749821-19-0 |
C13H14F2N7O+ |
![Canagliflozin Defluoro Impurity](/) |
Canagliflozin Defluoro Impurity |
|
|
![Dapagliflozin Impurity 6](/) |
Dapagliflozin Impurity 6 |
|
|
![Imatinib Impurity 7](/CAS/20180808/GIF/581076-64-4.gif) |
Imatinib Impurity 7 |
581076-64-4 |
C8H12N4 |
![4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylicacid, 5,6-dihydro-8-hydroxy-5-methyl-6-oxo-, ethyl ester](/CAS2/GIF/131666-45-0.gif) |
4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylicacid, 5,6-dihydro-8-hydroxy-5-methyl-6-oxo-, ethyl ester |
131666-45-0 |
C15H15N3O4 |
![2-アミノ-2-(4-ヘプチルフェネチル)-1,3-プロパンジオール](/CAS/20180808/GIF/745767-97-9.gif) |
2-アミノ-2-(4-ヘプチルフェネチル)-1,3-プロパンジオール |
745767-97-9 |
C18H31NO2 |
![Tenofovir Fumarate](/CAS/20180906/GIF/1246812-23-6.gif) |
Tenofovir Fumarate |
1246812-23-6 |
C21H34N5O9P |
![Prucalopride Impurity C](/CAS/20210111/GIF/1599434-55-5.gif) |
Prucalopride Impurity C |
1599434-55-5 |
C17H24ClN3O3 |
![Nilotinib Impurity 1](/CAS/20210111/GIF/641571-05-3.gif) |
Nilotinib Impurity 1 |
641571-05-3 |
C28H22F3N7O |
![Riociguat Impurtiy 1](/) |
Riociguat Impurtiy 1 |
|
|
![Riociguat Impurtiy 6](/CAS/20180808/GIF/1702271-98-4.gif) |
Riociguat Impurtiy 6 |
1702271-98-4 |
C18H17FN8 |
![Brimonidine Impurity E](/CAS/20180808/GIF/168329-48-4.gif) |
Brimonidine Impurity E |
168329-48-4 |
C9H8BrN5 |
![Dapagliflozin Impurity G](/) |
Dapagliflozin Impurity G |
|
|
![Dapoxetine Impurity B](/) |
Dapoxetine Impurity B |
|
|
![Fesoterodine Diol Dimer](/CAS/20180808/GIF/1428856-45-4.gif) |
Fesoterodine Diol Dimer |
1428856-45-4 |
C44H60N2O3 |
![Gimeracil Impurity](/CAS/20180808/GIF/17902-24-8.gif) |
Gimeracil Impurity |
17902-24-8 |
C8H9ClN2O3 |
![Pramipexole Impurity H](/) |
Pramipexole Impurity H |
|
|
![Rivaroxaban Impurity H](/CAS/20200515/GIF/1807455-76-0.gif) |
Rivaroxaban Impurity H |
1807455-76-0 |
C25H24Cl2N4O6S2 |
![Vonoprazan impurity A](/) |
Vonoprazan impurity A |
|
|
![5-ethyl 3-isopropyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate](/CAS/20200119/GIF/2170716-02-4.gif) |
5-ethyl 3-isopropyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
2170716-02-4 |
C22H29ClN2O5 |
![Ibrutinib impurity D](/) |
Ibrutinib impurity D |
|
|
![Mupirocin impurity A](/CAS/20180629/GIF/CB13053659.gif) |
Mupirocin impurity A |
|
C26H44O9 |
![FG-4592 intermediate7](/CAS/20200611/GIF/1509958-19-3.gif) |
FG-4592 intermediate7 |
1509958-19-3 |
C20H20N2O4 |
![Milnacipran Impurity 13](/CAS/20211123/GIF/710339-49-4.gif) |
Milnacipran Impurity 13 |
710339-49-4 |
C12H16NO+ |
![Urapidil Impurity A](/) |
Urapidil Impurity A |
|
|
![Tofacitinib Impurity I](/) |
Tofacitinib Impurity I |
|
|
![N-(3-chloro-4-fluorophenyl)-6 ,7-dimethoxyquinazolin-4-amine](/CAS/20200515/GIF/153437-78-6.gif) |
N-(3-chloro-4-fluorophenyl)-6 ,7-dimethoxyquinazolin-4-amine |
153437-78-6 |
C16H13ClFN3O2 |
![N-[4-[2-(メチルアミノ)エトキシ]ベンジル]-3,4-ジメトキシベンズアミド](/CAS/20200515/GIF/141996-97-6.gif) |
N-[4-[2-(メチルアミノ)エトキシ]ベンジル]-3,4-ジメトキシベンズアミド |
141996-97-6 |
C19H24N2O4 |
![Mirabegron Impurity](/CAS/20180808/GIF/1796931-48-0.gif) |
Mirabegron Impurity |
1796931-48-0 |
C21H24N4O2S |
![34-Methylcyanocobalamin](/CAS/20210111/GIF/38218-51-8.gif) |
34-Methylcyanocobalamin |
38218-51-8 |
C64H90CoN14O14P |
![Empagliflozin Impurity D](/) |
Empagliflozin Impurity D |
|
|
![Ipragliflozin Impurity 2](/) |
Ipragliflozin Impurity 2 |
|
|
![Nicergoline EP impurity F](/) |
Nicergoline EP impurity F |
|
|
![Mirabegron Impurity 4](/) |
Mirabegron Impurity 4 |
|
|
![Bisoprolol EP Impurity D](/CAS/20180629/GIF/1225195-71-0.gif) |
Bisoprolol EP Impurity D |
1225195-71-0 |
C26H40N2O5 |
![2-(4-イソブトキシフェニル)-4-メチルチアゾール-5-カルボン酸](/CAS/20180808/GIF/1206550-99-3.gif) |
2-(4-イソブトキシフェニル)-4-メチルチアゾール-5-カルボン酸 |
1206550-99-3 |
C15H17NO3S |
![(5S,8R,9S,10S,13S,14S)-10,13-dimethyl-1,5,6,7,8,9,10,11,12,13,15,16-dodecahydro-4H-cyclopenta[a]phenanthren-17(14H)-one](/CAS/20200119/GIF/14639-79-3.gif) |
(5S,8R,9S,10S,13S,14S)-10,13-dimethyl-1,5,6,7,8,9,10,11,12,13,15,16-dodecahydro-4H-cyclopenta[a]phenanthren-17(14H)-one |
14639-79-3 |
C19H28O |
![Cefuroxime Sodium Impurity](/CAS/20180629/GIF/CB13119214.gif) |
Cefuroxime Sodium Impurity |
|
C16H16N4NaO8S |
![2-Bromo (S)-Carbidopa](/CAS/20180808/GIF/43197-33-7.gif) |
2-Bromo (S)-Carbidopa |
43197-33-7 |
C10H13BrN2O4 |
![1-cyclopropyl-7-fluoro-8-methoxy-6-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid](/CAS/20200401/GIF/2205053-60-5.gif) |
1-cyclopropyl-7-fluoro-8-methoxy-6-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
2205053-60-5 |
C21H24FN3O4 |
![Brexpiprazole N-Oxide](/CAS/20200515/GIF/1191900-58-9.gif) |
Brexpiprazole N-Oxide |
1191900-58-9 |
C25H27N3O3S |
![2,6-Dibenzyloxyacetophenone](/CAS/20180906/GIF/3886-19-9.gif) |
2,6-Dibenzyloxyacetophenone |
3886-19-9 |
C22H20O3 |
![6-ブロモ-3,4,4A,5-テトラヒドロ-1H-ピリド[4,3-B]インドール-2(9BH)-カルボン酸(4AS,9BR)-エチル](/CAS/20180703/GIF/1059630-08-8.gif) |
6-ブロモ-3,4,4A,5-テトラヒドロ-1H-ピリド[4,3-B]インドール-2(9BH)-カルボン酸(4AS,9BR)-エチル |
1059630-08-8 |
C14H17BrN2O2 |
![diphenhydramine impurity](/CAS/20180703/GIF/CB83144868.gif) |
diphenhydramine impurity |
|
C17H21NO |
![1,1-dimethyl-4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)piperazin-1-ium iodide](/CAS/20180703/GIF/CB83146796.gif) |
1,1-dimethyl-4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)piperazin-1-ium iodide |
|
C18H23IN4S |
![2-(4-butoxy-3-cyanophenyl)-4-methylthiazole-5-carboxylic acid](/CAS/20180703/GIF/1657014-33-9.gif) |
2-(4-butoxy-3-cyanophenyl)-4-methylthiazole-5-carboxylic acid |
1657014-33-9 |
C16H16N2O3S |
![vildagliptin Impurity O](/CAS/20200611/GIF/2253194-12-4.gif) |
vildagliptin Impurity O |
2253194-12-4 |
C12H18N4O2 |
![methyl (41R,12S,13aR)-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate](/CAS/20210111/GIF/38990-17-9.gif) |
methyl (41R,12S,13aR)-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate |
38990-17-9 |
C21H26N2O3 |
![Canagliflozin Impurity 17](/CAS/20210111/GIF/1951467-28-9.gif) |
Canagliflozin Impurity 17 |
1951467-28-9 |
C24H23FO6S |
![Canagliflozin Impurity 22](/) |
Canagliflozin Impurity 22 |
|
|
![Carfilzomib Impurity 3](/) |
Carfilzomib Impurity 3 |
|
|
![Dolutegravir Impurity 4](/) |
Dolutegravir Impurity 4 |
|
|
![Febuxostat Impurity 20](/) |
Febuxostat Impurity 20 |
|
|
![Lenvatinib Impurity 1](/) |
Lenvatinib Impurity 1 |
|
|